Literature DB >> 23321320

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region.

Yuji Urabe1, Hidenori Ochi, Naoya Kato, Vinod Kumar, Atsushi Takahashi, Ryosuke Muroyama, Naoya Hosono, Motoyuki Otsuka, Ryosuke Tateishi, Paulisally Hau Yi Lo, Chizu Tanikawa, Masao Omata, Kazuhiko Koike, Daiki Miki, Hiromi Abe, Naoyuki Kamatani, Joji Toyota, Hiromitsu Kumada, Michiaki Kubo, Kazuaki Chayama, Yusuke Nakamura, Koichi Matsuda.   

Abstract

BACKGROUND & AIMS: We performed a genome-wide association study (GWAS) of hepatitis C virus (HCV)-induced liver cirrhosis (LC) to identify predictive biomarkers for the risk of LC in patients with chronic hepatitis C (CHC).
METHODS: A total of 682 HCV-induced LC cases and 1045 CHC patients of Japanese origin were genotyped by Illumina Human Hap 610-Quad bead Chip.
RESULTS: Eight SNPs which showed possible associations (p<1.0 × 10(-5)) at the GWAS stage were further genotyped using 936 LC cases and 3809 CHC patients. We found that two SNPs within the major histocompatibility complex (MHC) region on chromosome 6p21, rs910049 and rs3135363, were significantly associated with the progression from CHC to LC (pcombined=9.15 × 10(-11) and 1.45 × 10(-10), odds ratio (OR)=1.46 and 1.37, respectively). We also found that HLA-DQA1(*)0601 and HLA-DRB1(*)0405 were associated with the progression from CHC to LC (p=4.53 × 10(-4) and 1.54 × 10(-4) with OR=2.80 and 1.45, respectively). Multiple logistic regression analysis revealed that rs3135363, rs910049, and HLA-DQA1(*)0601 were independently associated with the risk of HCV-induced LC. In addition, individuals with four or more risk alleles for these three loci have a 2.83-fold higher risk for LC than those with no risk allele, indicating the cumulative effects of these variations.
CONCLUSIONS: Our findings elucidated the crucial roles of multiple genetic variations within the MHC region as prognostic/predictive biomarkers for CHC patients.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321320     DOI: 10.1016/j.jhep.2012.12.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  HLA class II associated with outcomes of hepatitis B and C infections.

Authors:  Akihiro Tamori; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  HLA DQB1 alleles are related with nonalcoholic fatty liver disease.

Authors:  Levent Doganay; Seyma Katrinli; Yasar Colak; Ebubekir Senates; Ebru Zemheri; Oguzhan Ozturk; Feruze Yilmaz Enc; Ilyas Tuncer; Gizem Dinler Doganay
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

3.  Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination.

Authors:  Nathaniel D Lambert; Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Vernon Shane Pankratz; Gregory A Poland
Journal:  J Infect Dis       Date:  2014-10-06       Impact factor: 5.226

4.  Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.

Authors:  Kentaro Matsuura; Valeria De Giorgi; Cathy Schechterly; Richard Y Wang; Patrizia Farci; Yasuhito Tanaka; Harvey J Alter
Journal:  Hepatology       Date:  2016-07-07       Impact factor: 17.425

5.  TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.

Authors:  Etsuko Iio; Kentaro Matsuura; Noritomo Shimada; Masanori Atsukawa; Norio Itokawa; Hiroshi Abe; Keizo Kato; Koichi Takaguchi; Tomonori Senoh; Yuichiro Eguchi; Hideyuki Nomura; Kai Yoshizawa; Jong-Hon Kang; Takeshi Matsui; Noboru Hirashima; Atsunori Kusakabe; Tomokatsu Miyaki; Kei Fujiwara; Kayoko Matsunami; Susumu Tsutsumi; Katsuhiko Iwakiri; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2018-10-31       Impact factor: 7.527

6.  Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.

Authors:  Masaya Sato; Mayuko Kondo; Ryosuke Tateishi; Naoto Fujiwara; Naoya Kato; Haruhiko Yoshida; Masataka Taguri; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 7.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

8.  Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.

Authors:  Paulisally Hau Yi Lo; Yuji Urabe; Vinod Kumar; Chizu Tanikawa; Kazuhiko Koike; Naoya Kato; Daiki Miki; Kazuaki Chayama; Michiaki Kubo; Yusuke Nakamura; Koichi Matsuda
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

9.  Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs.

Authors:  Takahiro Kishikawa; Motoyuki Otsuka; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Yuji Kondo; Masao Akanuma; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  Clinical significance of the CCR5delta32 allele in hepatitis C.

Authors:  Isabelle Morard; Sophie Clément; Alexandra Calmy; Alessandra Mangia; Andrea Cerny; Andrea De Gottardi; Meri Gorgievski; Markus Heim; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; David Semela; Stéphanie Pascarella; Pierre-Yves Bochud; Franco Negro
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.